Fortunately, the FDA has approved antipsychotic treatments that help manage these destructive symptoms, and more are in ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

There are many mechanisms at work here, but the blood sugar increase is probably secondary to the weight gain, rather than ...

A new report that lists what it calls the best nursing homes in the US finds that top-rated facilities continuously excel ...

AbbVie (NYSE:ABBV) has announced that its two phase 2 trials of a treatment for adults with schizophrenia missed its primary endpoint, sending shares in the drugmaker down sharply in premarket US ...

Management of adverse events is a major concern of clinicians who use antipsychotic drugs. The incidence of motor side effects is dose dependent. Atypical antipsychotic drugs are less likely to ...

Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to ...

Can large national health plans make an impact in reducing prescribing of high-risk medications to people with Alzheimer's ...

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...

The failure of emraclidine, which AbbVie obtained after acquiring Cerevel, may present a considerable advantage for rival BMS ...

Therefore, this drug should be avoided for 72 hours before sample collection but the patient should be monitored intensively in a clinical setting. • Antipsychotic drugs combined with ...